Schrödinger Q1 revenue $64.8M (+33%), net income $129.1M on $147M Nimbus gain

Schrodinger, Inc.

2023-Q1 EPS reported $1.75 revenue$64,782,000

Drug discovery revenue $32.6M (up 109% YoY) includes $25M BMS milestone for SOS1/KRAS program.
Software revenue $32.2M (down 3% YoY); gross margin 78%.
Cash from Nimbus TYK2 sale $147.3M; total cash and securities $532M at quarter-end.
Phase 1 dosing ongoing for SGR-1505 (MALT1) in B-cell malignancies and healthy volunteers.
Guidance reaffirmed: software revenue growth 13-17%, drug discovery $70-90M; operating expense growth to moderate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Schrodinger, Inc. reported first quarter 2023 results: revenue $64.8 million, net income $129.1 million. Guidance reaffirmed.

Period: first quarter 2023
Revenue: $64.8 million
Net income: $129.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports Strong First Quarter 2023 Financial Results Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Schrodinger, Inc. filing history →

Source: SEC EDGAR

accession 0001490978-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.